Beranda › Kanker Metastatik › Texas › McAllen
Uji klinis Kanker Metastatik di McAllen, TX
5 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar McAllen (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Texas Oncology - Central/South Texas, McAllen
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Menerima pesertaFase 3
- Nova Oncology, McAllen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Menerima pesertaFase 3
- Nova Oncology, McAllen
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Menerima pesertaFase 1/2
- Texas Oncology - Central South, McAllen
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Menerima pesertaFase 3
- Texas Oncology McAllen, McAllen
Uji klinis Kanker Metastatik di kota lain
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Studi lain di McAllen
- Degenerasi Makula6 studi
- Kanker Payudara4 studi
- Aterosklerosis4 studi
- Kaki Diabetes3 studi
- Gagal Jantung3 studi
- Atrofi Geografis3 studi
- Penyakit Kardiovaskular3 studi
- Obesitas3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.